Abstract
Introduction
Surgery is a risk factor for flares in people with gout. However, gout flares after endovascular interventional procedures are not well understood. The aim of this study was to evaluate the clinical features and risk factors for gout flare that develop during the postsurgical period including endovascular procedures.
Methods
We enrolled 222 patients with gout who developed postsurgical gout and 196 controls who had histories of gout but did not develop gout flares after surgery within 20 days. Clinical characteristics of patients who developed a postsurgical gout flare were compared with the controls.
Results
The rate of endovascular interventional procedures was higher (38.74% vs. 13.48%, P < 0.001) in the flare group than in the no-flare group and lower in orthopedic surgery (13.96% vs. 41.84%, P < 0.001). The Cox model showed that endovascular interventional procedures (HR, hazard ratio 1.752; 95% CI, confidence interval 1.126–2.724, P = 0.013) and presurgical uric acid levels of ≥ 7 mg/dl (HR 1.489; 95% CI 1.081–2.051, P = 0.015) were significantly associated with increased risks of postsurgical gout flare, and taking colchicine before surgery were significantly associated with decreased risk of postsurgical gout flare (HR 0.264; 95% CI 0.090–0.774, P = 0.015). There was no significant difference in the types of endovascular interventional procedures between the flare group and the no-flare group.
Conclusions
Patients with a history of gout should be more alert to recurrence gout flares after endovascular interventional procedures. Adequate presurgical control of serum uric acid levels and/or prophylactic treatment with colchicine will help prevent gout flares during the postsurgical period.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why carry out this study? |
Surgery increases the risk of gout flare; however, the endovascular interventional procedures associated with this risk are not well understood. |
We hypothesized that endovascular interventional procedures and uric acid-related factors influence postoperative gout flares. |
What was learned from the study? |
Endovascular interventional procedure and presurgical uric acid level of ≥ 7 mg/dl are risk factors for postoperative gout flares. Prophylactic treatment with colchicine is a protective factor. |
Introduction
Gout is one of the most common inflammatory joint diseases, caused by the deposition of urate crystals in the joints or soft tissue[1]. In China, Gout affects 1.1% of Chinese adults [2]. In addition to hyperuricemia, which is the most important risk factor for gout, surgery is another important independent risk factor causing an acute gout flare. Postoperative gout flares may lead to unnecessary antibiotic therapy, and increasing days of hospitalization by delaying early ambulation [3, 4].
Interventional radiology (IR) involves percutaneous puncture under the guidance of medical imaging equipment (angiography, fluoroscopy, computed tomography, magnetic resonance imaging, B-scan ultrasound, etc.) to perform minimally invasive diagnosis and treatment of diseases. Endovascular interventional radiology is among the most crucial procedures widely employed for treating vascular diseases due to its advantages over traditional open surgeries, including minimal invasiveness, shorter hospital stays, and reduced complications [5, 6]. Previous studies on postoperative gout flares have focused only on surgical procedures and did not include endovascular interventional procedures, and the results of these studies were different.
In this study, endovascular procedures were incorporated to assess the clinical characteristics and risk factors associated with gout flare during the postoperative period. The aim was to assist clinicians in better predicting, identifying, and managing gout flares both before and after surgery.
Methods
Patients
Subjects were selected from patients aged 18 years or older who had undergone surgery at the Second Affiliated Hospital, Zhejiang University School of Medicine from January 2020 to December 2021. Exclusion criteria included those having gout or gout-related complications as the primary admission diagnosis for surgery or having incomplete laboratory data or diagnosed as reactive arthritis or infectious arthritis. Gout flare was diagnosed by the consultant rheumatologist or attending doctors or the episode satisfied the 2015 ACR/EULAR gout classification criteria. The study was approved by the Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine (approval No. 2021-0783). The requirement for written informed consent was waived by the Ethics Committee owing to the retrospective nature of the study. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
Main Outcome Variable
The following were collected: (1) demographic data including age, gender, weight, height, and body mass index (BMI); (2) comorbidities, such as hypertension, diabetes, hypohepatia, renal insufficiency, fatty liver, and kidney stones; (3) laboratory results before surgery such as serum uric acid; (4) surgical factors such as medicines in the operation, body sites involved in surgery and operation duration; (5) medications before surgery, including urate-lowering agents, glucocorticoid, colchicine, diuretic, hypotensor, antidiabetic agent and aspirin; (6) postoperative nutrition and analgesic medication, which including desocine, non-steroidal anti-inflammatory drugs (used in the absence of gout flares), tramadol hydrochloride, buprenorphine, parecoxib, ketorolac tromethamine, oxycodone, methocarbamol, ibuprofen and codeine phosphate tablets, morphine.
Statistical Analysis
All statistical analyses were conducted using STATA statistical software (STATA13.1, StataCorp, College Station, TX, USA), and P < 0.05 was considered statistically significant. We used Kolmogorov–Smirnov tests to check the normality of continuous variables, after which we used t test in instances where the numerical variable had normal distribution, and we used the rank sum test if there was no normal distribution. Categorical variables were analyzed using Chi-square test. Time-dependent Cox proportional hazards regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs). The figures were done by software (GraphPad Prism 9, GraphPad Software, La Jolla, CA, USA).
Results
From January 2020 to December 2021, there were 1761 individuals who underwent surgery at the Second Affiliated Hospital of Zhejiang College School of Medicine with a history of gout. Among them, 277 patients were diagnosed with postoperative gout flares. Sixteen patients with gout-related complications requiring surgery and 39 patients with incomplete information were excluded, leaving 222 eligible patients for analysis. Among the patients without gout flares, 222 individuals were selected according to the random number method, 26 cases were excluded according to the exclusion criteria, (ten surgery of gout-related complications, one reactive arthritis, 15 incomplete information), and 196 patients without gout flare were finally enrolled as controls.
Clinical Features of Postsurgical Gout Flares
The clinical characteristics of the flare group and no-flare group are shown in the Table 1. Patients in the flare group were older than in no-flare group. Patients in the flare group who had combined hypertension, diabetes, and renal insufficiency were significantly more than those in the no-flare group. Colchicine (0.5–1.0 mg/day), postoperative pain medication and glucocorticoid were more frequently taken in the no-flare group than in the flare group, respectively. Diuretic, hypotensor, antidiabetic agents, and aspirin were more frequently taken in the flare group than in the no-flare group. However, the rate of postoperative nutritional support (both oral and intravenous) was higher in the flare group. Preoperative uric acid levels were significantly higher in the flare group than in the no-flare group, while the hemoglobin and eGFR (estimated glomerular filtration rate) were lower. For patients with comorbidities, we supplemented the specific data on relevant medications, as shown in Supplementary Materials Table 1.
The type of surgery was classified according to the surgical site, and the results of the analysis are detailed in the Table 1. The patients in the flare group more frequently underwent endovascular interventional procedures than the no-flare group. However, orthopedic surgery was more frequent in the no-flare group. The duration of surgery and anesthesia were significantly longer in the flare group than in the no-flare group, respectively, and the intraoperative use of sodium hyaluronate and compound betamethasone were less.
The uric acid-related factors in orthopedic surgery and endovascular surgery were analyzed in Supplementary Materials Table 2, which suggested that there were no statistically significant differences in uric acid levels, the proportion of uric acid higher than 7 mg/dl, colchicine, and uric acid-lowering agents.
Risk Factors for Postsurgical Gout
The analysis of whether different types of surgery were risk factors for postoperative gout flares is shown in detail in Fig. 1. Among them, endovascular interventional procedure was a risk factor (P < 0.001), while orthopedic surgery was a protective factor (P < 0.001).
To determine the impact of endovascular interventional procedure on postsurgical gout flare, a Cox regression analysis adjusted for potential confounding factors (Fig. 2) was performed. The Cox model showed that endovascular interventional procedures (HR 1.752; 95% CI 1.126–2.724, P = 0.013) and presurgical uric acid levels of ≥ 7 mg/dl (HR 1.489; 95% CI 1.081–2.051, P = 0.015) were significantly associated with increased risks of postsurgical gout flare, and taking colchicine before surgery were significantly associated with decreased risk of postsurgical gout flare (HR 0.264; 95% CI 0.090–0.774, P = 0.015).
A cumulative hazard plot is shown in Fig. 3. Patients undergoing endovascular interventional procedure were at greater risk of postsurgical gout flare.
Type of Endovascular Interventional Procedure and Postsurgical Gout
We divided the endovascular interventional procedures into three types, including radiofrequency catheter ablation, pacemaker implantation and treatment of intravascular lesions under the guidance of X-rays (percutaneous transluminal angioplasty, percutaneous endovascular stent implantation, etc.). Then we analyzed the types of endovascular interventional procedure, which is showed in Fig. 4. There was no significant difference in the types of endovascular interventional procedures between the flare group and the no-flare group by the χ2 test (P = 0.443).
Discussion
Recurrent gout flares are a major clinical burden of gout, and despite available uric acid-lowering therapies, the risk of recurrent gout remains high. Sixty-seven percent of patients who have already had a previous gout flare would have at least one flare within a year [7]. Surgery is an important trigger for gout flares, with studies finding that 17.2% of patients with gout will experience a gout flare after surgery, and observers in China have found this flare rate to be as high as 40.3% [8, 9].
No previous studies have included endovascular interventional procedures to analyze, and our study found that endovascular interventional procedures were an important risk factor for postoperative gout flares. There may be several reasons for this: (1) Inflammation from mechanical endothelial injury caused by endovascular interventional procedures may lead to gout flares. It has been found that percutaneous coronary intervention (PCI) causes mechanical endothelial injury and endothelial denudation, resulting in elevated inflammatory markers such as hyper-sensitivity CRP (hs-CRP), and this significantly raised inflammatory markers after the procedure suggests a close association with poor prognosis [10, 11]. Similar results have been found in radiofrequency ablation, and studies have shown that the concentration of vascular hemophilia factor (vWF), an important plasma component that is elevated when endothelial cells are injured or receive stimulation, is elevated 24 h after radiofrequency ablation, thus suggesting that radiofrequency ablation can also cause endothelial injury [12, 13]. Initial endothelial activation was related to leukocyte recruitment, which would release intracellular serine proteases [e.g., neutrophil elastase, histone G, and proteinase 3 (PR3)] in response to cell recruitment, causing MSU crystal-mediated cell injury and death, and secrete IL-1β to increase inflammation [14, 15]. Therefore, we speculate that endothelial damage induced by interventional procedures may recruit leukocytes and accelerate the inflammatory response caused by urate crystals, thus causing gout flares [16]. (2) Coronary microembolization (CME) is a common complication of percutaneous coronary intervention (PCI) [17]. It has been found that inflammatory responses in the myocardium after CME involved TLR4/MyD88/NF-κB signaling and the NLRP3 inflammasome, with increased expression levels of pro-inflammatory factors TNF-α, IL-1β [18]. Also, the TLR4/NF-κB pathway plays an important role in the pathogenesis of gout as well. The priming signal effectively promotes the transcriptional activation of NLRP3 inflammasome-containing genes such as NLRP3, pro-IL-1β, and pro-IL-18 in a TLR4/NF-κB pathway-dependent manner [19, 20].
The traditional anti-inflammatory and analgesic drugs for gout treatment include colchicine, NSAIDs, and glucocorticoids [21]. Our study showed that only taking colchicine before surgery was a protective factor for postoperative gout flares, which is consistent with previous findings [9, 22, 23]. The mechanism of colchicine is mainly to bind to β-microtubulin and inhibit cytoskeletal microtubule polymerization, thereby inhibiting the formation of NLPR3 inflammasomes and suppressing the inflammatory response to gout [21, 24]. This may be the reason why colchicine reduces gout flares after endovascular interventional procedures. Besides, colchicine has an endothelial protective effect [25], which can increase plaque stability and decrease plaque progression [26]. Adding low-dose (0.5 mg/day) colchicine to the optimal medical treatment significantly reduced the risk of acute coronary events, cardiovascular death, and resuscitated cardiac arrest [27, 28]. Therefore, prophylactic treatment with colchicine (0.5–1.0 mg/day) can prevent not only postoperative gout flares but also cardiovascular events, which we used if appropriate as a first-line option.
Previous studies have found that the rate of achieving target uric acid in patients with gout in China is low, with only 39.2% of patients reaching the target uric acid (6 mg/dl), even among those who have received long-term uric acid lowering therapy [29]. Therefore, we chose 7 mg/dl (the diagnosis of hyperuricemia) rather than 6 mg/dl as the cutoff. Our results suggested that presurgical uric acid level of ≥ 7 mg/dl before operation was a risk factor for postoperative gout flares, but taking uric acid-lowering agents was not associated with gout flares, which is consistent with previous findings [30]. Therefore, even though target uric acid (6 mg/dl) is difficult to achieve in the short term, controlling preoperative uric acid levels below 7 mg/dl remains an important method of preventing postoperative gout flares.
The limitations of this study are as follows. First, the study was a cross-sectional design with a single race and a small sample size. Second, in the collection of study data, although the exact risk factors were studied extensively, surgery-related factors (e.g., preoperative preparation, surgical technique, postoperative management) was not included. Third, ophthalmologic surgery was not included due to limitations in data collection. Therefore, the results of this study may not be fully applicable to all surgical options. A future well-designed study is needed to investigate the pathogenesis of postoperative gout flares.
Conclusions
Our study findings revealed that the endovascular interventional procedure was a significant risk factor for postoperative gout flares, but there was no significant difference in the types of endovascular interventional procedures for postoperative gout flares. Controlling preoperative uric acid levels below 7 mg/dl is crucial for preventing postoperative gout flares. Additionally, prophylactic treatment with colchicine may be effective in averting gout flares.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Dalbeth N, Gosling AL, Gaffo A, et al. Gout. Lancet. 2021;397:1843–55.
Zhu B, Wang Y, Zhou W, et al. Trend dynamics of gout prevalence among the Chinese population, 1990–2019: a Joinpoint and age-period-cohort analysis. Front Public Health. 2022;10:1008598.
Siu AL, Penrod JD, Boockvar KS, et al. Early ambulation after hip fracture: effects on function and mortality. Arch Intern Med. 2006;166:766–71.
Chen KJ, Huang YC, Yao YC, et al. Risk factors for postsurgical gout flares after thoracolumbar spine surgeries. J Clin Med. 2022;11.
Wang H, Wu J. A time-dependent offset field approach to simulating realistic interactions between beating hearts and surgical devices in virtual interventional radiology. Front Cardiovasc Med. 2022;9:1004968.
Hubert GJ, Hubert ND, Maegerlein C, et al. Association between use of a flying intervention team vs patient interhospital transfer and time to endovascular thrombectomy among patients with acute ischemic stroke in Nonurban Germany. JAMA. 2022;327:1795–805.
Yu KH, Chen DY, Chen JH, et al. Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018;21:772–87.
Craig MH, Poole GV, Hauser CJ. Postsurgical gout. Am Surg. 1995;61:56–9.
Zhuo Y, Cai X, Hou Z, et al. Postoperative recurrent gout flares: a cross-sectional study from China. J Clin Rheumatol. 2020;26:197–203.
Gach O, Legrand V, Biessaux Y, et al. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol. 2007;99:31–5.
Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol. 2010;55:1553–65.
Kornej J, Dinov B, Blann AD, et al. Effects of radiofrequency catheter ablation of atrial fibrillation on soluble P-selectin, von Willebrand factor and IL-6 in the peripheral and cardiac circulation. PLoS ONE. 2014;9: e111760.
Bulava A, Slavík L, Fiala M, et al. Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins. J Interv Card Electrophysiol. 2004;10:271–9.
Cho JS, Guo Y, Ramos RI, et al. Neutrophil-derived IL-1β is sufficient for abscess formation in immunity against Staphylococcus aureus in mice. PLoS Pathog. 2012;8: e1003047.
Joosten LAB, Crişan TO, Bjornstad P, et al. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol. 2020;16:75–86.
Haskard DO, Landis RC. Interactions between leukocytes and endothelial cells in gout: lessons from a self-limiting inflammatory response. Arthritis Res. 2002;4(Suppl 3):S91–7.
Su Q, Li L, Sun Y, et al. Effects of the TLR4/Myd88/NF-κB signaling pathway on NLRP3 inflammasome in coronary microembolization-induced myocardial injury. Cell Physiol Biochem. 2018;47:1497–508.
Su Q, Lv X, Sun Y, et al. Role of TLR4/MyD88/NF-κB signaling pathway in coronary microembolization-induced myocardial injury prevented and treated with nicorandil. Biomed Pharmacother. 2018;106:776–84.
Liu YR, Wang JQ, Li J. Role of NLRP3 in the pathogenesis and treatment of gout arthritis. Front Immunol. 2023;14:1137822.
Charoenwutthikun S, Chanjitwiriya K, Roytrakul S, et al. A wild rice-derived peptide R14 ameliorates monosodium urate crystals-induced IL-1β secretion through inhibition of NF-κB signaling and NLRP3 inflammasome activation. PeerJ. 2023;11: e15295.
Shi C, Zhou Z, Chi X, et al. Recent advances in gout drugs. Eur J Med Chem. 2023;245: 114890.
Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Curr Rheumatol Rep. 2014;16:400.
Jeong H, Jeon CH. Clinical characteristics and risk factors for gout flare during the postsurgical period. Adv Rheumatol. 2019;59:31.
Yang LP. Oral colchicine (Colcrys): in the treatment and prophylaxis of gout. Drugs. 2010;70:1603–13.
Pamuk BO, Sari I, Selcuk S, et al. Evaluation of circulating endothelial biomarkers in familial Mediterranean fever. Rheumatol Int. 2013;33:1967–72.
Cimmino G, Loffredo FS, De Rosa G, et al. Colchicine in athero-thrombosis: molecular mechanisms and clinical evidence. Int J Mol Sci. 2023;24.
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505.
Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–10.
Zhang P, Chen M, Wang J, et al. Febuxostat therapy for patients with gout and stage 2–4 CKD: a retrospective study. Rheumatol Ther. 2022;9:1421–34.
Kang EH, Lee EY, Lee YJ, et al. Clinical features and risk factors of postsurgical gout. Ann Rheum Dis. 2008;67:1271–5.
Funding
This work was supported by the National Natural Science Foundation of China under Grant number 81571577 and Key Research and Development Program of Zhejiang Province under Grant number 2020C03044. No funding or sponsorship was received for the publication of this article. The Rapid Service Fee was funded by the authors.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Shunjie Hu, Xiaoyong Lu, Zitao Wang, Peiyu Zhang, and Huaxiang Wu. The first draft of the manuscript was written by Shunjie Hu and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of Interest
Xiaoyong Lu, Zitao Wang, Peiyu Zhang, and Huaxiang Wu declare that they have no competing interests. Shunjie Hu has changed her affiliation from the Second Affiliated Hospital, Zhejiang University School of Medicine to Shaoxing People's Hospital during the completion of the manuscript.
Ethical Approval
The study was approved by the Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine (approval No. 2021-0783). The requirement for written informed consent was waived by the Ethics Committee owing to the retrospective nature of the study. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Hu, S., Wang, Z., Zhang, P. et al. Endovascular Interventional Procedure is a Significant Risk Factor of Postsurgical Gout: A Retrospective Cohort Study. Rheumatol Ther 11, 51–60 (2024). https://doi.org/10.1007/s40744-023-00617-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40744-023-00617-2